Saturday, July 04, 2020 9:09:41 PM
If 2-73 is capable of improving cellular function then perhaps the brain cells responsible for the production of dopamine can go back to being healthy and alleviate symptoms that way - just my hope however faint -
" One of the most common neurologic disorders that elders experience, Parkinson’s disease (PD) is a devastating diagnosis affecting approximately 2 of every 1,000 older adults. Although there is currently no cure and current PD treatments help alleviate only the symptoms rather than the disease’s progression, fresh hope lies in new research focused on neuroprotection.
PD, the causes of which are unknown, is a chronic, progressive brain disorder that belongs to a larger class of disorders called movement disorders. In PD, one particular population of brain cells—those that produce a chemical messenger called dopamine—become impaired and are lost over time. “The loss of these brain cells causes circuits in the brain to function abnormally, and those abnormal circuits result in movement problems,” says Beth-Anne Sieber, PhD, program director for the Neurodegeneration Cluster at the National Institute of Neurological Disorders and Stroke."
Seems like PD is difficult to even diagnose let alone treat -
"A PD diagnosis is usually guided by presenting symptoms because there is no blood or other test to diagnose the disease. Although one might think a brain scan such as an MRI may be successful in detecting PD, “in a scan like magnetic resonance imaging, which shows structural changes in the brain, they appear normal in Parkinson’s disease because these cells that die off are a very small population, yet they have a huge impact on the patient’s movement,” says Sieber.
Diagnosis can also be complicated by the fact that other disorders can have similar symptoms to those exhibited with PD. After older adults are put on PD treatments for their symptoms, a more definitive diagnosis can be made. “Parkinson’s disease may be difficult to diagnose initially, but the classic PD symptoms and response to medications are supportive factors,” says Sieber."
https://www.todaysgeriatricmedicine.com/news/ex_06309_03.shtml
" One of the most common neurologic disorders that elders experience, Parkinson’s disease (PD) is a devastating diagnosis affecting approximately 2 of every 1,000 older adults. Although there is currently no cure and current PD treatments help alleviate only the symptoms rather than the disease’s progression, fresh hope lies in new research focused on neuroprotection.
PD, the causes of which are unknown, is a chronic, progressive brain disorder that belongs to a larger class of disorders called movement disorders. In PD, one particular population of brain cells—those that produce a chemical messenger called dopamine—become impaired and are lost over time. “The loss of these brain cells causes circuits in the brain to function abnormally, and those abnormal circuits result in movement problems,” says Beth-Anne Sieber, PhD, program director for the Neurodegeneration Cluster at the National Institute of Neurological Disorders and Stroke."
Seems like PD is difficult to even diagnose let alone treat -
"A PD diagnosis is usually guided by presenting symptoms because there is no blood or other test to diagnose the disease. Although one might think a brain scan such as an MRI may be successful in detecting PD, “in a scan like magnetic resonance imaging, which shows structural changes in the brain, they appear normal in Parkinson’s disease because these cells that die off are a very small population, yet they have a huge impact on the patient’s movement,” says Sieber.
Diagnosis can also be complicated by the fact that other disorders can have similar symptoms to those exhibited with PD. After older adults are put on PD treatments for their symptoms, a more definitive diagnosis can be made. “Parkinson’s disease may be difficult to diagnose initially, but the classic PD symptoms and response to medications are supportive factors,” says Sieber."
https://www.todaysgeriatricmedicine.com/news/ex_06309_03.shtml
They said "You should be on the stage!" (As in - the next stage out of town)
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
